Nuvectis Pharma Stock Fundamentals
| NVCT Stock | USD 8.85 0.50 5.99% |
Nuvectis Pharma fundamentals help investors to digest information that contributes to Nuvectis Pharma's financial success or failures. It also enables traders to predict the movement of Nuvectis Stock. The fundamental analysis module provides a way to measure Nuvectis Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nuvectis Pharma stock.
Nuvectis |
Nuvectis Pharma Company Return On Equity Analysis
Nuvectis Pharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Nuvectis Pharma Return On Equity | -1.73 |
Most of Nuvectis Pharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nuvectis Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Nuvectis Pharma has a Return On Equity of -1.7341. This is 92.77% lower than that of the Biotechnology sector and 95.24% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Nuvectis Pharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Nuvectis Pharma's current stock value. Our valuation model uses many indicators to compare Nuvectis Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nuvectis Pharma competition to find correlations between indicators driving Nuvectis Pharma's intrinsic value. More Info.Nuvectis Pharma is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Nuvectis Pharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Nuvectis Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nuvectis Pharma's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nuvectis Pharma could also be used in its relative valuation, which is a method of valuing Nuvectis Pharma by comparing valuation metrics of similar companies.Nuvectis Pharma is currently under evaluation in return on equity category among its peers.
Nuvectis Fundamentals
| Return On Equity | -1.73 | ||||
| Return On Asset | -0.66 | ||||
| Current Valuation | 176.79 M | ||||
| Shares Outstanding | 23.39 M | ||||
| Shares Owned By Insiders | 45.35 % | ||||
| Shares Owned By Institutions | 6.92 % | ||||
| Number Of Shares Shorted | 1.56 M | ||||
| Price To Book | 20.11 X | ||||
| EBITDA | (22.9 M) | ||||
| Net Income | (19 M) | ||||
| Cash And Equivalents | 13.57 M | ||||
| Cash Per Share | 0.93 X | ||||
| Total Debt | 8.89 M | ||||
| Current Ratio | 5.20 X | ||||
| Book Value Per Share | 0.50 X | ||||
| Cash Flow From Operations | (12.25 M) | ||||
| Short Ratio | 11.14 X | ||||
| Earnings Per Share | (1.11) X | ||||
| Target Price | 18.5 | ||||
| Number Of Employees | 13 | ||||
| Beta | 0.22 | ||||
| Market Capitalization | 207.01 M | ||||
| Total Asset | 18.61 M | ||||
| Retained Earnings | (73.25 M) | ||||
| Working Capital | 9.71 M | ||||
| Net Asset | 18.61 M |
About Nuvectis Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nuvectis Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nuvectis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nuvectis Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company was incorporated in 2020 and is based in Fort Lee, New Jersey. Nuvectis Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nuvectis Stock Analysis
When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.